[Effect of intralesional treatment with emetine hydrochloride on Leishmania (Viannia) braziliensis in hamsters].
The therapeutic effect of the emetine hydrochloride alkaloid administered intralesionally was compared with that of standard parenteral treatment with Glucantime in outbred male hamsters experimentally infected with 4 x 10(3) amastigotes of Leishmania (Viannia) braziliensis. Both chemotherapeutic agents reduced significantly (P < 0.01) the average lesion sizes in experimental animals in comparison with those untreated. The alkaloid infiltration was found to be as effective as the antimonial injection for clinical resolution. The ultrastructural effects on the Leishmania parasites exposed to emetine were observed mainly in the inner cytoplasm, which appeared disorganized, pycnotic and with loss of morphological definition; however, any known emetine hydrochloride action mechanism factor could not be directly related with ultrastructure effects detected on leishmanial parasites. Smears, conventional histopathology, culture in NNN medium and indirect immunoperoxidase method showed viable amastigotes in nodules and/or scars of all the evaluated hamsters 75 to 230 days after the end of treatment. These findings suggest that measurement of the size of cutaneous leishmania lesions does not appear to be a valid criterion for evaluating the efficiency of chemotherapy in experimental LT. Detection of leishmania parasites in the lesion scars, supports the hypothesis that man could be considered as an domestic reservoir.
Cazorla
D
D
Unidad de Parasitología y Medicina Tropical, Universidad Nacional Experimental Francisco de Miranda, Coro, Estado Falcón, Venezuela.
Yépez
J
J
Añez
N
N
Sánchez de Mirt
A
A
D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002921:Cicatrix / Q000469:parasitology*; D006224:Cricetinae; D003593:Cytoplasm / Q000187:drug effects / Q000648:ultrastructure; D004197:Disease Reservoirs; D004353:Drug Evaluation, Preclinical; D004640:Emetine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007124:Immunoenzyme Techniques; D015552:Injections, Intralesional; D007892:Leishmania braziliensis / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification / Q000648:ultrastructure; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000469:parasitology / Q000473:pathology; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D008647:Mesocricetus; D008854:Microscopy, Electron; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D014617:Vacuoles / Q000187:drug effects / Q000648:ultrastructure
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D004640:Emetine